Close Menu

Penn State Hershey Children's Hospital and Serametrix will collaborate on developing a serum-based assay that will measure autoantibodies to help doctors predict which patients are likely to respond to a brain cancer immunotherapy being developed by the hospital.

The partnership, announced this week, is part of the Pediatric Cancer Immunotherapy Program at Penn State Hershey Children's Hospital. Within this program, researchers are developing new treatments for children with relapsed tumors that aim to bolster their immune response against cancer cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.

A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.

The Los Angeles Times reports that only a third of California students meet the state's new science standards.

In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.

Feb
20
Sponsored by
Thermo Fisher Scientific

This webinar will discuss the use of 3’ mRNA sequencing to reduce the cost of gene expression studies on Illumina NGS systems.

Mar
18
Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.